Neoadjuvant Immunotherapy Strategies in HPV-Related Head-and-Neck Cancer.

IF 0.4 Q4 OTORHINOLARYNGOLOGY

Current Otorhinolaryngology Reports Pub Date : 2022-03-01 DOI:10.1007/s40136-021-00389-9

Shin Saito, Hirofumi Shibata, Douglas Adkins, Ravindra Uppaluri

{"title":"Neoadjuvant Immunotherapy Strategies in HPV-Related Head-and-Neck Cancer.","authors":"Shin Saito, Hirofumi Shibata, Douglas Adkins, Ravindra Uppaluri","doi":"10.1007/s40136-021-00389-9","DOIUrl":null,"url":null,"abstract":"Purpose of review: Herein, we review current evidence and future directions of neoadjuvant immunotherapy in HPV-related head and neck squamous cell carcinoma (HNSCC) by describing published data and ongoing clinical trials.Recent findings: Although HNSCCs have shown response to immune checkpoint inhibitors in recurrent/metastatic disease, a limited number of patients benefit from this treatment. There is an expanding interest in clarifying the clinical benefit of immunotherapy in earlier stage disease setting including at initial presentation. Neoadjuvant immunotherapy for HPV-related HNSCCs represents a rational approach, as these cancers bear strong viral antigens.Summary: The majority of patients with HPV-related HNSCC have good prognosis and treatment de-intensification strategies are under evaluation to decrease toxicity and maintain efficacy. On the other hand, a subset of patients with HPV-related HNSCC have a poorer prognosis and additional treatment options are need to improve outcome. Multiple clinical trials are ongoing to evaluate whether neoadjuvant immunotherapy will achieve these goals.","PeriodicalId":36165,"journal":{"name":"Current Otorhinolaryngology Reports","volume":"10 1","pages":"108-115"},"PeriodicalIF":0.4000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385129/pdf/nihms-1776354.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Otorhinolaryngology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40136-021-00389-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Purpose of review: Herein, we review current evidence and future directions of neoadjuvant immunotherapy in HPV-related head and neck squamous cell carcinoma (HNSCC) by describing published data and ongoing clinical trials.

Recent findings: Although HNSCCs have shown response to immune checkpoint inhibitors in recurrent/metastatic disease, a limited number of patients benefit from this treatment. There is an expanding interest in clarifying the clinical benefit of immunotherapy in earlier stage disease setting including at initial presentation. Neoadjuvant immunotherapy for HPV-related HNSCCs represents a rational approach, as these cancers bear strong viral antigens.

Summary: The majority of patients with HPV-related HNSCC have good prognosis and treatment de-intensification strategies are under evaluation to decrease toxicity and maintain efficacy. On the other hand, a subset of patients with HPV-related HNSCC have a poorer prognosis and additional treatment options are need to improve outcome. Multiple clinical trials are ongoing to evaluate whether neoadjuvant immunotherapy will achieve these goals.

查看原文本刊更多论文

hpv相关头颈癌的新辅助免疫治疗策略。

综述目的:本文通过描述已发表的数据和正在进行的临床试验，回顾了hpv相关头颈部鳞状细胞癌(HNSCC)新辅助免疫治疗的现有证据和未来方向。最近的研究发现:尽管HNSCCs对复发/转移性疾病的免疫检查点抑制剂有反应，但有限数量的患者从这种治疗中受益。有一个扩大的兴趣澄清免疫治疗的临床效益在早期疾病设置，包括在最初的表现。hpv相关HNSCCs的新辅助免疫治疗是一种合理的方法，因为这些癌症具有强病毒抗原。摘要:大多数hpv相关HNSCC患者预后良好，治疗去强化策略正在评估中，以降低毒性并保持疗效。另一方面，一部分hpv相关HNSCC患者预后较差，需要额外的治疗选择来改善结果。目前正在进行多项临床试验，以评估新辅助免疫疗法是否能达到这些目标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Otorhinolaryngology Reports Medicine-Surgery

CiteScore

1.00

自引率

16.70%

发文量

期刊介绍： This journal aims to offer expert review articles on the most significant recent developments in the field of otorhinolaryngology. By providing clear, insightful, balanced contributions, the journal intends to serve all those involved in the diagnosis and treatment of ear, nose, throat, and head and neck disorders. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas across the field. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An Editorial Board of more than 20 internationally diverse members reviews the annual table of contents, ensures that topics include emerging research, and suggests topics of special importance to their country/region. Topics covered may include chronic rhinosinusitis; implantable devices; neurolaryngology; otolaryngic allergy; robotic surgery; sleep apnea; skull base surgery; thyroid surgery; and quality and outcomes.